

Nonalcoholic Steatohepatitis Market Analysis 2032: Epidemiology, Therapies, FDA Approvals and Companies by DelveInsight

Nonalcoholic Steatohepatitis companies are Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly, Madrigal Pharmaceuticals, Terns, and more.


ALBANY, NEW YORK, UNITED STATES, April 4, 2024 /EINPresswire.com/ -- DelveInsight's "Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Nonalcoholic Steatohepatitis (NASH) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Nonalcoholic Steatohepatitis (NASH) market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Nonalcoholic Steatohepatitis (NASH) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Nonalcoholic Steatohepatitis (NASH) market.

Request for a Free Sample Report @ [Nonalcoholic Steatohepatitis Market Forecast](#)

Key facts of the Nonalcoholic Steatohepatitis (NASH) Market Report are:

- According to DelveInsight, Nonalcoholic Steatohepatitis (NASH) market size is expected to grow at a decent CAGR by 2032.
- Leading Nonalcoholic Steatohepatitis companies working in the market are Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis



Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, and others.

- Key Nonalcoholic Steatohepatitis (NASH) Therapies expected to launch in the market are TERN-101, SNP-610, LJN452 (tropifexor + licogliflozin), PXL065, ALS-L1023, PF-06865571 + PF-05221304, PF-06835919, PF-06865571, ORMD-0801, Norucholic acid, NNC0194-0499, MN-001, MK-3655, MET642, MET409, LPCN 1144, LIK066, Leronlimab, ALN-HSD, RXC007, LR19018, LR19131, CM101, Leu-Mit-Sil (NS-0200), IN-A010, Efruxifermin (EFX), Efinopegdutide, JKB-122, CS0159 (Linafexor), CRV431, Chiglitazar sodium, ARO-PNPLA3, ECC4703, BOS-580, HEC96719, GSK4532990, BIO89-100, Cotadutide solution, Firsocostat, EPY001a, Emricasan, BMS-986036, BIO89-100, BI 456906, BFKB8488A, AXA1125, ASC 41, GS-9674 (Cilofexor), ZSP1601, and others.
- In March 2023, Aligos Therapeutics presented Phase 1 data for its thyroid receptor-beta (THR- β) agonist candidate, ALG-055009, at the 15th Paris Hepatology Conference, taking place virtually March 27 – 29, 2023.

Nonalcoholic Steatohepatitis (NASH) Overview

Nonalcoholic steatohepatitis (NASH) is a type of liver inflammation and damage caused by fat accumulation. It is one of the numerous disorders known as nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease is divided into two types: isolated fatty liver, in which only fat accumulates, and nonalcoholic steatohepatitis, in which fat, inflammation, and liver cell damage accumulate. NASH does not usually cause symptoms. Most people with NASH feel fine and are unaware that they have it. As NASH progresses and liver damage worsens, a patient may experience fatigue, weight loss, general weakness, and acne in the upper right part of the belly. Screening for nonalcoholic fatty liver disease in the general population is not advised. It is usually considered after discovering unexplained liver enzyme levels or imaging reveals hepatic steatosis. A patient's medical history, a physical exam, and tests for nonalcoholic steatohepatitis are used by doctors.

Learn more about NASH treatment algorithms in different geographies, and patient journeys.

Contact to receive a sample @ https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Nonalcoholic Steatohepatitis (NASH) Market

The Nonalcoholic Steatohepatitis (NASH) market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Nonalcoholic Steatohepatitis (NASH) market trends by analyzing the impact of current Nonalcoholic Steatohepatitis (NASH) therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Nonalcoholic Steatohepatitis (NASH) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Nonalcoholic Steatohepatitis (NASH) market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Nonalcoholic Steatohepatitis (NASH) market in 7MM is expected to witness a major change in the study period 2019-2032.

Nonalcoholic Steatohepatitis (NASH) Epidemiology

The Nonalcoholic Steatohepatitis (NASH) epidemiology section provides insights into the historical and current Nonalcoholic Steatohepatitis (NASH) patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Nonalcoholic Steatohepatitis (NASH) market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Nonalcoholic Steatohepatitis (NASH) Epidemiology @ [Non-alcoholic Steatohepatitis \(NASH\) Market Dynamics and Trends](#)

Nonalcoholic Steatohepatitis (NASH) Drugs Uptake

This section focuses on the uptake rate of the potential Nonalcoholic Steatohepatitis (NASH) drugs recently launched in the Nonalcoholic Steatohepatitis (NASH) market or expected to be launched in 2019-2032. The analysis covers the Nonalcoholic Steatohepatitis (NASH) market uptake by drugs, patient uptake by therapies, and sales of each drug.

Nonalcoholic Steatohepatitis (NASH) Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Nonalcoholic Steatohepatitis (NASH) market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Nonalcoholic Steatohepatitis (NASH) Pipeline Development Activities

The Nonalcoholic Steatohepatitis (NASH) report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Nonalcoholic Steatohepatitis (NASH) key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Nonalcoholic Steatohepatitis (NASH) pipeline development activities @ [Nonalcoholic Steatohepatitis \(NASH\) Therapies and Drugs](#)

Nonalcoholic Steatohepatitis (NASH) Therapeutics Assessment

Major key companies are working proactively in the Nonalcoholic Steatohepatitis (NASH) Therapeutics market to develop novel therapies which will drive the Nonalcoholic Steatohepatitis

(NASH) treatment markets in the upcoming years are Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, Akerio Therapeutics, Merck Sharp & Dohme LLC, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, Sunshine Lake Pharma, GSK plc., Future Medicine, Gilead Sciences, ENYO Pharma, Histogen, and others.

Nonalcoholic Steatohepatitis (NASH) Report Key Insights

1. Nonalcoholic Steatohepatitis (NASH) Patient Population
2. Nonalcoholic Steatohepatitis (NASH) Market Size and Trends
3. Key Cross Competition in the Nonalcoholic Steatohepatitis (NASH) Market
4. Nonalcoholic Steatohepatitis (NASH) Market Dynamics (Key Drivers and Barriers)
5. Nonalcoholic Steatohepatitis (NASH) Market Opportunities
6. Nonalcoholic Steatohepatitis (NASH) Therapeutic Approaches
7. Nonalcoholic Steatohepatitis (NASH) Pipeline Analysis
8. Nonalcoholic Steatohepatitis (NASH) Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Nonalcoholic Steatohepatitis (NASH) Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Nonalcoholic Steatohepatitis (NASH) Competitive Intelligence Analysis
4. Nonalcoholic Steatohepatitis (NASH) Market Overview at a Glance
5. Nonalcoholic Steatohepatitis (NASH) Disease Background and Overview
6. Nonalcoholic Steatohepatitis (NASH) Patient Journey
7. Nonalcoholic Steatohepatitis (NASH) Epidemiology and Patient Population
8. Nonalcoholic Steatohepatitis (NASH) Treatment Algorithm, Current Treatment, and Medical Practices
9. Nonalcoholic Steatohepatitis (NASH) Unmet Needs
10. Key Endpoints of Nonalcoholic Steatohepatitis (NASH) Treatment
11. Nonalcoholic Steatohepatitis (NASH) Marketed Products
12. Nonalcoholic Steatohepatitis (NASH) Emerging Therapies
13. Nonalcoholic Steatohepatitis (NASH) Seven Major Market Analysis
14. Attribute Analysis
15. Nonalcoholic Steatohepatitis (NASH) Market Outlook (7 major markets)
16. Nonalcoholic Steatohepatitis (NASH) Access and Reimbursement Overview
17. KOL Views on the Nonalcoholic Steatohepatitis (NASH) Market

18. Nonalcoholic Steatohepatitis (NASH) Market Drivers
19. Nonalcoholic Steatohepatitis (NASH) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Ankit Nigam

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/701075864>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.